SORTINO, Giovanni
SORTINO, Giovanni
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
2014-01-01 Rolfo, C; Sortino, G; Smits, E; Passiglia, F; Bronte, G; Castiglia, M; Russo, A; Santos, ES; Janssens, A; Pauwels, P; Raez, L
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario
2015-01-01 Bronte, G.; Sortino, G.; Passiglia, F.; Rizzo, S.; Lo Vullo, F.; Galvano, A.; Bazan, V.; Rolfo, C.; Russo, A.
Monoclonal antibodies in gastrointestinal cancers
2013-01-01 Bronte, G.; Cicero, G.; Cusenza, S.; Galvano, A.; Musso, E.; Rizzo, S.; Sortino, G.; Roselli, M.; Bazan, V.; Fiorentino, E.; Russo, A
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?
2015-01-01 Bronte, G.; Silvestris, N.; Castiglia, M.; Galvano, A.; Passiglia, F.; Sortino, G.; Cicero, G.; Rolfo, C.; Peeters, M.; Bazan, V.; Fanale, D.; Giordano, A.; Russo, A.
Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules
2011-01-01 Caraglia, M.; Santini, D.; Bronte, G.; Rizzo, S.; Sortino, G.; Rini, G.; Di Fede, G.; Russo, A.
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status
2016-01-01 Bronte, G.; Franchina, T.; Alù, M.; Sortino, G.; Celesia, C.; Passiglia, F.; Savio, G.; Laudani, A.; Russo, A.; Picone, A.; Rizzo, S.; De Tursi, M.; Gambale, E.; Bazan, V.; Natoli, C.; Blasi, L.; Adamo, V.; Russo, A.
The role of targeted therapy for gastrointestinal tumors
2014-01-01 Rolfo, C.; Bronte, G.; Sortino, G.; Papadimitriou, K.; Passiglia, F.; Fiorentino, E.; Marogy, G.; Russo, A.; Peeters, M